The “Gut-Prostate Axis” is  fundamental in the development of prostate disease and yourgutplus is first and only probiotic proven to slow prostate cancer progression including Benign Prostate Hypertrophy (BPH) and Prostate cancer development progression and prognosis.

The underlying mechanisms include inflammation, oxidative stress, and reduced immune surveillance. Laboratory models models have shown that altering the gut microbiome can slow PCa progression.  In men with PCa, lower levels of gut Lactobacillus strains and antibiotic use have been linked to both a higher rate of PCa incidence and biochemical recurrence but  until the Yourphyto study presented at ASCO GU 2025 no probiotic has been shown to reduce the risk

Despite the increasing choice of probiotics available on the market, claiming to have benefits, Yourgutplus was the Worlds first and currently only probiotic which has demonstrate a benefit in Men with prostate cancer in a formal scientific trial. The result presented in the World’s largest prostate cancer conference in San Francisco this year showed that Yourgutplus:

  • Slowly PSA progression
  • Reduced cancer size on MRI
  • Improved urinary symptom and erectile function
  • Reduced markers of inflammation
  • Improved overall strength

Yourgutplus hero image

References probiotics and prostate cancer

  1. Fujita K, Matsushita M, De Velasco MA, et al. The gut-prostate axis: a new perspective of prostate cancer biology through the gut microbiome. Cancers (Basel). 2023 Mar 21;15(5):1375. doi:10.3390/cancers15051375. PMID: 36900168.​
  1. Kustrimovic N, Bombelli R, Baci D, et al. Microbiome and prostate cancer: a novel target for prevention and treatment. Int J Mol Sci. 2023 Jan 12;24(2):1511. doi:10.3390/ijms24021511. PMID: 36675055.​
  1. Porter CM, Shrestha E, Sfanos KS et al. The microbiome in prostate inflammation and prostate cancer. Vol. 21, Prostate Cancer and Prostatic Dis. Nat Publ Group. 2018:345–354.
  1. Yadav A, Kaushik M, Tiwari P, et al. From microbes to medicine: harnessing the gut microbiota to combat prostate cancer. Microb Cell. 2024 May 23;11:187-197. doi:10.15698/mic2024.05.824. PMID: 38803512.
  1. Katongole P, Sande OJ, Joloba M, et al. The human microbiome and its link in prostate cancer risk and pathogenesis. Infect Agent Cancer. 2020 Aug 31;15:53. doi: 10.1186/s13027-020-00319-2. PMID: 32884579; PMCID: PMC7460756.
  1. Pernigoni N, Zagato E, Calcinotto A, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021 Oct 8; 374(6564):216-224. doi: 10.1126/science.abf8403. Epub 2021 Oct 7. PMID: 34618582.
  1. Terrisse S, Goubet AG, Ueda K, et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother Cancer. 2022 Mar;10(3):e004191. doi: 10.1136/jitc-2021-004191. PMID: 35296557; PMCID: PMC8928383.
  1. Liss MA, White JR, Goros M, et al. Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. Eur Urol. 2018 Nov; 74(5):575-582. doi: 10.1016/j.eururo.2018.06.033. Epub 2018 Jul 12. PMID: 30007819; PMCID: PMC6716160.
  1. Alanee S, El-Zawahry A, Dynda D, et al. A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis. Prostate. 2019 Jan;79(1):81-87. doi:10.1002/pros.23713. Epub 2018 Aug 16. PMID: 30117171.​
  1. Kim JH, Seo H, Kim S, et al. Biochemical Recurrence in Prostate Cancer Is Associated with the Composition of Lactobacillus: Microbiome Analysis of Prostatic Tissue. Int J Mol Sci. 2023 Jun 21;24(13):10423. doi:10.3390/ijms241310423. PMID: 37445601; PMCID: PMC10341780.​
  1. Golombos DM, Ayangbesan A, O’Malley P, et al. The Role of Gut Microbiome in the Pathogenesis of Prostate Cancer: A Prospective, Pilot Study. Urology. 2018 Jan; 111:122-128. doi: 10.1016/j.urology.2017.08.039. Epub 2017 Sep 6. PMID: 28888753.

continue reading

Related Posts